Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
79 results about "Hepatic lipid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hepatic lipid metabolism in health and disease. (A) Dietary lipids are emulsified in the intestinal tract by bile acids (BAs). Hydrolyzed lipids are absorbed by enterocytes and packed into nascent chylomicrons (NCs). NCs enter the bloodstream via the thoracic duct where they receive important apoproteins (apoE; apoC-II) from HDL.
Plant drug for treatment of liver disease
The present invention related to safe plant drug for treatment of liver disease, specifically, this invention proves a safe plant drug Schisandrin and its preparation. Schisandrin has the following pharmaceutical functions: increasing tumor suppresson genes express activity, decreasing activity of oncogenes, increasing immune function, increasing liver DNA synthesis, decreasing serum alamine aminotransferase activity, increasing glutathione level, increasing glutathione reductase activity, decreasing lipid peroxidation of liver, increasing hepatic microsomal monooxygenases activity, increasing ATP content in liver, increasing energy metabolism activity, decreasing density lipoprotein oxidation, protecting gastrointestinal function, increasing killer cell activity, increasing complement activity, decreasing induced liver cancer activity and decreasing grown of cancer cells.
Owner:ZHAO XINXIAN
Plant drug for treatment of liver disease
Owner:ZHAO XINXIAN
Oral polymeric membrane feruloyl esterase producing bacteria formulation
InactiveUS20100047320A1Reducing serumReducing hepatic lipidBiocideOrganic active ingredientsDiseaseBacteroides
The present invention relates to an oral formulation to lower serum or hepatic lipid and triglyceride concentrations, hepatic inflammation and / or insulin resistance in a patient comprising live feruloyl esterase producing microorganisms alone or in association with a pharmaceutically acceptable carrier resistant to gastric conditions, and wherein the microorganisms are wild type, genetically modified, or combination thereof. The present invention is also directed to an oral formulation to lower serum or hepatic lipid and triglyceride concentrations, hepatic inflammation and / or insulin resistance in a patient, which comprises polymeric microcapsules containing live feruloyl esterase producing microorganisms in suspension in a pharmaceutically acceptable carrier, wherein said microcapsules are semipermeable and resistant to gastro-intestinal conditions, and wherein said microorganism are wild type, genetically modified, or combination thereof as well as methods of preventing or improving liver diseases and disorders and uses thereof.
Owner:MCGILL UNIV
Chinese medicament preparation with sobering-up, blood fat-reducing, liver-protecting and cardio-cerebrovascular-protecting functions
ActiveCN101485861AHas the function of harmonizing the spleen and stomachReduce lipid peroxidation damageNervous disorderMetabolism disorderFormularyNutmeg extract
The invention relates to a traditional Chinese medicine preparation having functions of neutralizing the effect of alcoholic drink, reducing blood fat and protecting the liver and cardio-cerebral blood vessels, which comprises the following compositions: 20 to 80 percent of pollen pini, 10 to 70 percent of kudzu root extract, 5 to 50 percent of nutmeg extract and 5 to 30 percent of auxiliary materials. The traditional Chinese medicine preparation is health-care food prepared from pure natural food, namely the pollen pini, kudzu roots and nutmeg which are taken as main raw materials by a reasonable formula, specially aims to people suffering from chronic alcohol drinking, fat people and patients suffering from hypertension, hyperlipemia and hyperglycemia and chronic diseases, and achieves the aim of protecting chemical liver damage by protecting the liver and resisting lipid overoxidation damage of the liver caused by alcoholism. The pollen pini contains rich antioxidative substances, and can lighten lipid overoxidation damage of alcohol on the liver, strengthen metabolism of fatty acid in hepatocyte, and reduce fat deposition in the hepatocyte; the nutmeg has the function of regulating spleen and stomach; and the kudzu roots also have the function of relieving cerebral vasospasm, so that the traditional Chinese medicine preparation achieves the aim of relieving symptoms such as headache, stomach upset, dyspepsia and poor health after drinking.
Owner:承德畅达生物科技有限公司
Lachnum sp., extracellular polysaccharide thereof and application of extracellular polysaccharide in lipid-lowering liver-favoring medicaments
InactiveCN102250778ANo side effectsEffective in lowering blood fatOrganic active ingredientsFungiLipid formationSide effect
The invention discloses Lachnum sp., an extracellular polysaccharide thereof and application of the extracellular polysaccharide in preparing lipid-lowering liver-favoring medicaments. The invention is characterized in that a Lachnum sp. strain with the collection number of CCTCC (China Center for Type Culture Collection) No: M 2011196 is activated and inoculated to a fermentation culture medium, thus preparing the Lachnum sp. extracellular polysaccharide. When the administration dosage is 150-300 mg / (kg bw), the prepared Lachnum sp. extracellular polysaccharide can significantly lower the levels of serum lipid and liver lipid and atherosis index of high-lipid mice, and increase the level of serum high-density lipoprotein cholesterol and the excretion amount of feces lipid. When the administration dosage is 75-300 mg / (kg bw), the prepared Lachnum sp. extracellular polysaccharide can significantly lower the activity of serum aminotransferase and malondialdehyde content in liver tissues of high-lipid mice, and increase the activity of sudismase in the liver tissues. The prepared Lachnum sp. extracellular polysaccharide has obvious effects of lowering blood lipid, lowering liver lipid, and treating hepatic injury and dysfunction caused by high lipid, has no toxic or side effects, and can be prepared into tablets or capsules for clinical application.
Owner:HEFEI UNIV OF TECH
Application of nicotinamide riboside in preparing drugs for treating non-alcoholic steatohepatitis
InactiveCN104622886AIncrease useHelp preventOrganic active ingredientsDigestive systemNicotinamide ribosideLiver fibrosis
The invention relates to an application of nicotinamide riboside in preparing drugs for treating non-alcoholic steatohepatitis. According to the application, a non-alcoholic steatohepatitis animal model is adopted to prove that the nicotinamide riboside is capable of reducing the liver lipid content, the liver inflammations and the liver fibrosis degree of the animal model and prompt that the nicotinamide riboside can be applied to preparing the drugs for treating the non-alcoholic steatohepatitis. The application of the nicotinamide riboside is expanded, a new way is provided for treating the non-alcoholic steatohepatitis, and therefore, the non-alcoholic steatohepatitis can be prevented and prognosed favorably.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Method for treating or preventing nonalcoholic fatty liver disease
InactiveUS20160271210A1Readily apparentOrganic active ingredientsPeptide/protein ingredientsInsulin resistanceHepatic lipid
A method for treating or preventing non-alcoholic fatty liver disease is disclosed. By promoting the expression of six-transmembrane protein of prostate 2 (STAMP2) in liver cells, the method can be useful in improving the abnormalities in lipid metabolism in the liver, and also improving insulin resistance, thereby preventing or treating a non-alcoholic fatty liver disease.
Owner:DONG A UNIV RES FOUND FOR IND ACAD COOP
Use of parabacteroides goldsteinii to treat fatty liver disease
ActiveCN109419814AAdjust physiological functionBacteria material medical ingredientsDigestive systemEccentric hypertrophyBacteroides tectus
Owner:CHANG GUNG BIOTECH
Application of GGPPS genes in preparation of medicines for treating non-alcoholic fatty liver disease
InactiveCN104415349AReduce lipid accumulationDecelerationGenetic material ingredientsDigestive systemAlanine aminotransferaseAspartate transaminase
The invention provides an application of GGPPS serving as a target for treating non-alcoholic fatty liver disease. A GGPPS antagonist disclosed by the invention can reduce genetic expression related to lipid accumulation of the liver. The liver-specific knockout GGPPS disclosed by the invention is capable of retarding the lipid accumulation and degeneration of the liver, reducing the level of aspartate transaminase (AST) and alanine aminotransferase (ALT) and protecting the liver functions.
Owner:NANJING UNIV
Agent for preventing or ameliorating obesity
The present invention provides a method for preventing or ameliorating obesity, for inhibiting accumulation of visceral fat, for inhibiting accumulation of liver lipid, for preventing or ameliorating fatty liver, including using a material for a pharmaceutical product or food, which has inhibitory actions on body weight increase, accumulation of visceral fat and accumulation of liver lipid. The present invention is also directed to a method for preventing or ameliorating obesity, a method for inhibiting accumulation of visceral fat, a method for inhibiting accumulation of liver lipid, and a method for preventing or ameliorating fatty liver, which methods include administering potassium alginate to a subject in need thereof or having the subject take potassium alginate.
Owner:KAO CORP
Application of baicalein extract in preparation of medicament for controlling hyperlipidemic fatty liver
InactiveCN101732411AReduce liver weightLower hepatic factorOrganic active ingredientsMetabolism disorderBaicaleinFatty liver
The invention discloses application of a baicalein extract in preparation of a medicament for controlling hyperlipidemic fatty liver. The baicalein extract is proved to have effect of preventing the hyperlipidemic fatty liver in pharmacological experiments, and is particularly used for reducing the liver weight and the liver coefficient of rats and reducing the content of the blood fat and liver lipid.
Owner:苏州中药研究所有限公司
Application of dioscin in preparation of liver-protecting pharmaceutical preparation
ActiveCN101837004AInhibit peroxidationInhibit fatty degenerationOrganic active ingredientsDigestive systemLactate dehydrogenaseSide effect
The invention discloses an application of dioscin in preparation of a liver-protecting pharmaceutical preparation. The pharmaceutical preparation can obviously inhibit increase of activity of aminotransferase and lactate dehydrogenase due to medicines (carbon tetrachloride or paracetamol) and alcohol, and reduce the liver indices, thereby performing the liver-protecting function; the pharmaceutical preparation can enhance the activity of SOD, reduce the content of MDA, increase the content of GSH and inhibit liver lipide overoxidation induced by medicines (carbon tetrachloride or paracetamol); and the pharmaceutical preparation can also reduce the content of TG and TC and inhibit the liver steatosis caused by alcohol. The dioscin can be used as the raw material to prepare various preparation formulations for clinic applications according to pharmaceutic related requirements and clinic requirements, such as tablets, capsules, injections, oral liquids, granules and the like. The invention is safe (no toxicity or side effect), convenient, economical and the like.
Owner:DALIAN MEDICAL UNIVERSITY
Application of E3 ubiquitin ligase RNF14 in preparation of drug for treating fatty liver and related diseases
InactiveCN108339113AImprove securityPeptide/protein ingredientsMetabolism disorderUbiquitin ligaseFhit gene
The invention discloses application of E3 ubiquitin ligase RNF14 in preparation of a drug for treating fatty liver and related diseases, and belongs to a new use of the RNF14. In the present invention, a L02 cell line overexpressed by human normal liver cell line L02 and the RNF14 is used as an experimental object, and the gene function of the RNF14 is studied by a fatty liver cell model co-induced by palmitic acid (PA) and oleic acid (OA). The study finds that RNF14 overexpression can significantly improve lipid accumulation in liver cells, indicating that the RNF14 can protect the liver cells from fatty degeneration, and the RNF14 plays a protective role in liver lipid metabolic diseases. Since the RNF14 is an endogenous protein kin the body, the RNF14 is highly safe as the drug.
Owner:WUHAN UNIV
Application of great burdock root polysaccharide in preparation of drug for treating non-alcoholic fatty liver disease
PendingCN111084784AReduce liver weightPositive therapeutic effectOrganic active ingredientsDigestive systemInflammatory factorsEthanol precipitation
The invention relates to application of great burdock root polysaccharide in preparation of a drug for treating non-alcoholic fatty liver disease (NAFLD). The great burdock root polysaccharide provided by the invention is prepared from great burdock roots, and is prepared by carrying out enzyme inactivation, extraction, filtration, suction filtration, centrifugation, ethanol precipitation, macroporous resin decolorization, trichloroacetic acid deproteinization and the like; and the great burdock root polysaccharide has an average molecular weight of 3000-5000 Da. According to the application of the great burdock root polysaccharide in the preparation of the drug for treating the NAFLD, NAFLD mouse models are established through induction by high fat diet (HFD), and are used for study on activity of the burdock root polysaccharide in NAFLD treatment; and it is found that the great burdock root polysaccharide is capable of significantly reducing liver weight and liver index so as to reduce accumulation of liver lipid, alleviate liver damage and regulate inflammatory factors so as to achieve positive therapeutic effects on the NAFLD.
Owner:博德生物技术(德州)有限公司
Method to prepare ganoderma lucidum polysaccharides possessing protective activities on fatty liver disease
ActiveUS20170028003A1Reduce lipid levelReduce liver weightOrganic active ingredientsDigestive systemFatty liverLiver lipid
The present invention provides a method to prepare polysaccharides from Ganoderma lucidum. The prepared polysaccharides can reduce liver weight and liver lipid content in humans and animals. The prepared polysaccharides can therefore be used to prevent and treat fatty liver disease.
Owner:CHANG GUNG BIOTECH
(Pro) resin receptor (P) RR gene and application of inhibitor of gene
The invention discloses a function and application of a (pro) resin receptor [(pro) resin receptor, (P) RR] inhibitor in nonalcoholic fatty livers and fat diseases. Under the background of C57 mice, (P) RR liver specificity knock-out / know-down mice are used as experimental objects, according to a fat mouse model which is induced through high-fat feed, and it is proved through a result that the size of the liver (P) RR knock-out mice is remarkably small, and the fat tissue in the mouse bodies is remarkably reduced; after the mice are fed with the high-fat feed, the increase amplitude of the weight of the mice is low, fat is not generated, the blood glucose content is low, through results of oil red dyeing, liver lipid measurement and the like, it is explained that the liver function of theliver (pro) resin receptor knock-out mice is remarkably better than that of contrasted fatty mice, the fatty liver lesion of the mice is remarkably improved, the stored lipid is remarkably reduced, and the blood glucose content is lowered. Therefore, (P) RR can be used as a medicine target of screening treatment of type-II diabetes, nonalcoholic fatty livers and fat diseases, and the inhibitor of(P) RR can be applied to preparation of medicine for treating type-II diabetes, nonalcoholic fatty livers and fat diseases.
Owner:SHENZHEN UNIV
Method to treat fatty liver disease using Parabacteroides goldsteinii
ActiveUS10111915B1Lower Level RequirementsReduce weightBiocideBacteria material medical ingredientsEccentric hypertrophyHepatic lipid
The present invention describes a method to reduce blood aspartate transaminase level, liver weight, hepatic lipid accumulation and hepatocyte hypertrophy by administering the probiotic bacterium Parabacteroides goldsteinii to a subject showing signs of fatty liver disease. This probiotic bacterium can therefore be used to treat fatty liver disease.
Owner:CHANG GUNG BIOTECH
Application of PSMB8 and PSMB8 inhibitor to preparation of medicine for treating fatty liver and related diseases
ActiveCN108130370AWith deteriorating fatty liverWith associated diseasesMicrobiological testing/measurementDigestive systemWild typeHigh fat
The invention discloses application of PSMB8 and a PSMB8 inhibitor to preparation of medicine for treating fatty liver and related diseases. Primary hepatocytes of C57BL / 6 wild type mice and PSMB8 knock-down C57BL / 6 mice are separated; the functions of PSMB8 gene are studied by a palmitate and oleic acid stimulation induced liver cell lipid accumulation model. The result proves that when the PSMB8expression is lowered, the PA+OA stimulation induced primary hepatocyte lipid accumulation is obviously reduced, i.e., the PSMB8 gene can promote the development and progression of fatty liver and related diseases; in an HFHC (high fat and high cholesterol) induced WT mouse fatty liver disease model, PR-957 can obviously inhibit HFHC induced weight increase, white grease increase and liver lipidaccumulation; the development and progression of the fatty liver and related diseases are inhibited. Therefore the PSMB8 provides a target for developing medicine for preventing, relieving and / or treating the fatty liver and related diseases.
Owner:武汉惠康达科技有限公司
Functions and applications of centrifugal force and shearing stress response gene 1 in fatty liver and diabetes mellitus
ActiveCN104001188AImprove fatty liverImprove diabetesMetabolism disorderGenetic material ingredientsDiabetes mellitusFatty liver
The invention discloses functions and applications of RECS1 in the fatty liver and the diabetes mellitus, and belongs to the field of functions and applications of genes. An RECS1 gene knockout mouse and a wild type C57 mouse are used as experimental subjects, through a model of the fatty liver and the diabetes mellitus which are induced by high-fat diets, the result shows that compared with the wild type C57 mouse, glycometabolism of the RECS1 gene knockout mouse is disorderly, fatty liver lesion is severe, and lipid accumulation is remarkably increased. It explains that the RECS1 has the adjustment and control capacity for maintaining the steady state of glycometabolism and has the liver lipid removal capacity and fatty liver forming resistance. Thus, the functions of the RECS1 in the fatty liver and the diabetes mellitus are found and the functions are mainly reflected in the effects on alleviating fatty liver and diabetes mellitus. For the functions of the RECS1, the RECS1 can be used for preparing medicine for treating the fatty liver and the diabetes mellitus.
Owner:武汉惠康达科技有限公司
Crtc2/Creb compound blocking polypeptide and derivative medicinal polypeptide and application thereof
ActiveCN109666066ARegulatory activityEfficient membrane penetration efficiencyPolypeptide with localisation/targeting motifPeptide/protein ingredientsFatty liverBlood lipids
The invention relates to Crtc2 / Creb compound blocking polypeptide and derivative medicinal polypeptide and application thereof. The amino acid sequence of the Crtc2 / Creb compound blocking polypeptideis shown in SEQ ID NO:1, and the Crtc2 / Creb compound blocking polypeptide can be used for preparing drugs for treating obesity, fatty liver, hyperlipemia and type-2 diabetes. The medicinal polypeptidecomprises a blocking function structure area and a membrane penetrating function structure area which are formed by a targeted-inhibition Crtc2 / Creb compound, wherein the amino acid sequence of the blocking function structure area formed by targeted-inhibition Crtc2 / Creb compound is shown in SEQ ID NO:1. The medicinal polypeptide has obvious effects on adjustment of blood sugar and blood fat andinhibition of liver lipid deposition and can be used as a treatment drug for treating metabolic diseases such as obesity, fatty liver and type-2 diabetes alone or in other auxiliary treatment modes.
Owner:上海锐赛生物科技(集团)有限公司
Drug combination composition for type 2 diabetes and liver injury and application of drug combination composition
ActiveCN112807438AReduce food intakeImprove fasting body weightOrganic active ingredientsMetabolism disorderSide effectThiazolidinedione
The invention provides a drug combination composition for type 2 diabetes and liver injury and an application of the drug combination composition, and belongs to the field of biological medicine. The drug combination composition comprises selenium-enriched probiotics and thiazolidinedione medicine pioglitazone, and experiments of a type 2 diabetes mouse model constructed by combining high-fat feeding with STZ injection find that after the selenium-enriched probiotics DD98 and the pioglitazone are combined for administration, the weight and fasting blood glucose of the mouse can be obviously improved, liver lipid deposition, oxidative stress and inflammation levels can be reduced, and liver tissue damage can be relieved, so that the administration dosage of the pioglitazone is reduced, and a basis is provided for clinically avoiding side effects of the pioglitazone.
Owner:JIANGSU DAYSEBIOTECH LTD +1
Application of pleurotus eryngii mycelium polysaccharide from solid-state fermentation
PendingCN110227082AReduce lipid accumulationSafe and effective fat-lowering methodOrganic active ingredientsMetabolism disorderIntestinal microorganismsGut flora
The present invention discloses an application of a pleurotus eryngii mycelium polysaccharide from solid-state fermentation (PESF). The active polysaccharide (PESF) with a hypolipidemic function is produced by a solid-state fermentation method of pleurotus eryngii mycelia. In a mouse model in vivo hypolipidemic mechanism, an oral administration of a certain dose of the PESF can regulate intestinalmicroflora, significantly promotes growth of Lactobacillus and inhibits major micro-organism genus of staphylococcus, corynebacterium, aerococcus, etc., thus restores intestinal flora imbalance caused by a high-fat diet to a certain degree, finally inhibits absorption of exogenous lipids in intestinal tract, and thus reduces accumulation of blood lipids and liver lipids in body. The pleurotus eryngii polysaccharide is analyzed and confirmed to have biofunctional activity of regulating structure and functions of the intestinal microflora, and a significant correlation is found between polysaccharide hypolipidemic activity and polysaccharide intestinal microflora-regulating function.
Owner:NANJING NORMAL UNIVERSITY
Extract for promoting lipid metabolism of liver, resisting inflammation and reducing enzyme content, and preparation method thereof
InactiveCN109106730AImprove lipid metabolismEnhanced Absorption MechanismAntipyreticYeast food ingredientsHepatic lipidBiology
Owner:CHANGCHUN HEALTH FUTURE MEDICINE TECH CO LTD
Application of cordate houttuynia extract as adenylate-activated protein kinase activator in preparing medicine for improving metabolic syndrome
InactiveCN110403997AImprove heart dysfunctionImprove metabolic syndromeMetabolism disorderDigestive systemSide effectHouttuynia
The invention relates to an application of a cordate houttuynia extract as an adenylate-activated protein kinase activator in preparing a medicine for improving metabolic syndrome. The cordate houttuynia extract is a water-soluble extract of a dried part of a houtuynia sulfite plant, an extraction solvent is distilled water, an extraction ratio is 20:1, and the appearance of the product is yellow-brown powder; The cordate houttuynia extract acts to protect mitochondrial function and anti-oxidation by activating an AMPK-PGC-1alpha / Nrf2 signaling pathway and simultaneously up-regulating mitochondrial production and biphasic enzyme pathways, further improves the metabolic disorders associated with hyperlipidemia, liver lipid accumulation and cardiac dysfunction, and delays the occurrence anddevelopment of metabolic syndrome. The cordate houttuynia extract has no obvious side effects, and is a safe, simple and effective drug.
Owner:XI AN JIAOTONG UNIV
Use of dehydroeburicoic acid from antrodia camphorata in the treatment or prevention of diabetes and hyperlipidemia
ActiveUS20170216384A1Decreasing SREBP mRNA levelDecrease in blood total cholesterol （TC） levelOrganic active ingredientsMetabolism disorderPhosphorylationTG - Triglyceride
The present invention provides a method for treating type 1 diabetes, hyperlipidemia or hepatic lipid accumulation by using dehydroeburicoic acid, as well as a method for decreasing levels of blood glucose, plasma total cholesterol, and triglyceride, and increasing insulin levels; and a method for decreasing hepatic balloon degeneration; and increasing expression levels of membrane GLUT4 and phospho-Akt in myotubes; and enhancing expression levels of membrane glucose transporter 4 (GLUT4) in skeletal muscle, and phospho-AMPK in both skeletal muscle and liver tissue using dehydroeburicoic acid.
Owner:SHIH CHUN CHING
Magnolol and honokiol and method for preventing and treating fatty liver syndrome of laying hens by using magnolol and honokiol
InactiveCN112220781APromote fat depositionImprove convenienceHydroxy compound active ingredientsDigestive systemFatty liverHonokiol
The invention discloses magnolol and honokiol and a method for preventing and treating fatty liver syndrome of laying hens by using the magnolol and the honokiol. When the magnolol and the honokiol are applied to daily ration of laying hens, liver lipid accumulation can be effectively reduced, and the serum triglyceride level can be reduced. The expression of genes FASN and SCD1 related to fatty acid synthesis of the liver of the laying hen is remarkably reduced. The egg laying performance reduction of the cage-rearing laying hens caused by the fatty liver syndrome is relieved; the death and culling rate is reduced. And the magnolol and the honokiol have a synergistic effect in regulating liver lipid metabolism. The invention discloses an appropriate composition proportion of the magnololand the honokiol in preparation of feed additives or medicines for preventing and treating fatty liver syndrome of laying hens for the first time.
Owner:INST OF ANIMAL SCI & VETERINARY HUBEI ACADEMY OF AGRI SCI
Application of malonic-acid-modified fullerene C70 in preparation of medicine for treating non-alcoholic fatty liver disease
PendingCN110960553AInhibit lipid accumulationImprovement of lipid accumulationMetabolism disorderDigestive systemFibrosisBULK ACTIVE INGREDIENT
The invention discloses application of malonic-acid-modified fullerene C70 in preparation of a medicine for treating the non-alcoholic fatty liver disease. The medicine that uses the C70-malonic acidderivative as the active ingredient and is used for preventing, relieving and / or treating the non-alcoholic fatty liver disease and related diseases has the following advantages: firstly, the pharmacodynamic effect is obvious, the C70-malonic acid derivative can obviously inhibit lipid accumulation in primary hepatocytes of mice and obvious changes can be seen in 10 micrometers; in addition, the C70-malonic acid derivative also has an obvious improvement effect on liver lipid accumulation and fibrosis generated by HFHC diet induction; secondly, the malonic-acid-modified fullerene C70 can effectively reduce the damage of a carbon cage in a fullerene modification process, so that the pharmacodynamic activity of the fullerene body is better retained; and thirdly, the C70-malonic acid derivative has a determined molecular structure, problems that other water-soluble fullerene derivatives have no determined structure and are difficult in quality control are solved, and the patent medicine is realized conveniently.
Owner:武汉赛莱亚生物科技有限公司
Construction and application of microRNA-212-3P sponge based on recombinant adeno-associated virus 8
ActiveCN111471716AReduce lipid accumulationClearly targetedOrganic active ingredientsSpecial deliveryHepatic DiseasesMicroRNA
The invention relates to construction and application of a microRNA-212-3P sponge based on a recombinant adeno-associated virus 8. Reduction of the expression of miR-212-3P of the liver can reduce accumulation of liver lipid, and nonalcoholic fatty liver diseases caused by high fat diets can be prevented. The microRNA-212-3P sponge is constructed, and is delivered based on a rAAV8 carrier. A genetherapy is confirmed to be notable in effects on accumulation of the liver lipid and reduction of content of serum lipid, and favorable experiment NAFLD prevention and treatment effects are achieved.A new tool is provided for gene therapy of the nonalcoholic fatty liver diseases.
Owner:SHANGHAI TONGJI HOSPITAL
Applications of pegylated curcumin derivative
InactiveCN106581044AOrganic active ingredientsAntipyreticReverse cholesterol transportPhosphorylation
The invention belongs to the field of pharmaceutical chemistry, and in particular relates to novel applications of pegylated curcumin derivative, especially the applications of the pegylated curcumin derivative in preparing medicines for preventing or treating fatty liver diseases and atherosclerosis. The experiment proves that the pegylated curcumin derivative can reduce the level of triglyceride in the blood, activate the phosphorylation of cyclic-AMP response element binding protein (CREB), negatively regulate nuclear transcription receptor PPAR gamma closely related to lipid metabolism, reduce the CD36 expression of the lever tissue caused by high fat diet, reduce the intake of fatty acid of the liver, reduce the lipid formation of the liver, and improve the fatty degeneration of the liver. The pegylated curcumin derivative further can improve the level of high density lipoprotein cholesterol, promote the reverse cholesterol transport, reduce the CD36 expression of macrophages, reduce the intake of oxidized low density lipoprotein, alleviate the bubblization of the macrophages, and reduce the deposition of lipid on the endangium and the formation of artery atherosclerotic plaque.
Owner:THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV
Novel application of 4-hydroxyisoleucine
InactiveCN108078973AReduce accumulationNo side effectsOrganic active ingredientsMetabolism disorderDrugLow-density lipoprotein
The invention relates to an application of 4-hydroxyisoleucine in preparation of weight losing drugs or non-alcoholic fatty liver disease protecting drugs or healthcare food, that is, an application of the 4-hydroxyisoleucine in preparation of drugs for treating obesity and non-alcoholic fatty liver diseases. Oral preparations, capsules, tablets, granules and the like can be produced. Experiment find that 4-hydroxyisoleucine can effectively reduce weight, gathering of fat in the body, content of total cholesterol, triglyceride and low density lipoprotein in plasma and glutamic oxalacetic transaminase, protect the liver function, relieve fatty liver, reduce accumulation of liver lipid and safely and effectively reduce weight, reduce lipid and protect the liver for groups requiring obesity treatment.
Owner:ZHENGZHOU UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com